ISIN | LU2488093530 |
---|---|
Valor Number | 119401713 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class B CHF Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 88.33 CHF | 05.09.2024 |
---|---|---|
Previous Price * | 88.31 CHF | 04.09.2024 |
52 Week High * | 98.66 CHF | 15.05.2024 |
52 Week Low * | 79.97 CHF | 09.11.2023 |
NAV * | 88.33 CHF | 05.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 73,165,228 | |
Unit/Share Assets *** | 8,989 | |
Trading Information SIX |
YTD Performance | -3.31% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
---|---|---|
1 month | +3.10% |
05.08.2024 - 05.09.2024
05.08.2024 05.09.2024 |
3 months | -7.06% |
05.06.2024 - 05.09.2024
05.06.2024 05.09.2024 |
6 months | -5.67% |
05.03.2024 - 05.09.2024
05.03.2024 05.09.2024 |
1 year | -6.00% |
05.09.2023 - 05.09.2024
05.09.2023 05.09.2024 |
2 years | -11.67% |
20.03.2023 - 05.09.2024
20.03.2023 05.09.2024 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Pacira BioSciences Inc | 3.94% | |
---|---|---|
Penumbra Inc | 3.93% | |
ResMed Inc | 3.92% | |
Sage Therapeutics Inc | 3.89% | |
Hikma Pharmaceuticals PLC | 3.87% | |
Organon & Co Ordinary Shares | 3.84% | |
Intra-Cellular Therapies Inc | 3.83% | |
DexCom Inc | 3.69% | |
Allogene Therapeutics Inc | 3.69% | |
Centene Corp | 3.67% | |
Last data update | 30.04.2023 |
TER *** | 1.22% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.00% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |